Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Crinetics Pharmaceuticals, Inc. - Common Stock
(NQ:
CRNX
)
46.69
-0.70 (-1.49%)
Streaming Delayed Price
Updated: 12:45 PM EST, Dec 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Crinetics Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
Crinetics Pharmaceuticals Earnings Preview
↗
February 27, 2024
Via
Benzinga
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
February 14, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 12, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 23, 2024
Via
Benzinga
Analyst Scoreboard: 4 Ratings For Crinetics Pharmaceuticals
↗
December 19, 2023
Via
Benzinga
8 Analysts Have This to Say About Crinetics Pharmaceuticals
↗
November 20, 2023
Via
Benzinga
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 10, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 28, 2023
Via
Benzinga
11 Analysts Have This to Say About Crinetics Pharmaceuticals
↗
October 24, 2023
Via
Benzinga
Why Crinetics Pharmaceuticals Stock Soared This Week
↗
September 15, 2023
A positive late-stage trial readout fueled a major rally in the drugmaker's shares.
Via
The Motley Fool
Endocrine Diseases-Focused Crinetics Pharmaceuticals Highlights Favorable Initial Findings From Mid-Stage Study
↗
December 19, 2023
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) released initial findings from its ongoing open-label Phase 2 carcinoid syndrome (CS) study of paltusotine, an oral, once-daily investigational compound...
Via
Benzinga
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
December 18, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 11, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
November 20, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
October 11, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END
Via
FinancialNewsMedia
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
10 Health Care Stocks Whale Activity In Today's Session
↗
October 09, 2023
Via
Benzinga
7 Speculative Stocks Set to Explode Higher
↗
October 03, 2023
On the search for high-risk, high-reward opportunities? Consider taking a look at these seven speculative stocks.
Via
InvestorPlace
Top 4 Health Care Stocks That Should Keep You Up At Night
↗
September 21, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
September 20, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Up 83% in 5 Days, Is Crinetics Pharmaceuticals a Buy?
↗
September 19, 2023
Despite good results in phase 3 trials, there are barriers to its drug candidate's success.
Via
The Motley Fool
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
September 12, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
What's Going On With Crinetics Pharmaceuticals Stock?
↗
September 12, 2023
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares are trading higher Tuesday.
Via
Benzinga
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
September 11, 2023
From
Crinetics Pharmaceuticals, Inc.
Via
GlobeNewswire
Nasdaq Rises Over 1%; Hostess Brands Shares Spike Higher
↗
September 11, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.29% to 34,676.52 while the NASDAQ rose 1.16% to 13,920.60. The S&P...
Via
Benzinga
Topics
Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 11, 2023
Via
Benzinga
Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
September 11, 2023
Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
